Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 5/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11884635 | 0.98 | PAOX (0.48) | PAOXLTA4HALDH1A1CA1ACHE | |
| SCHEMBL9547901 | 0.93 | ALDH1A1 (0.43) | PAOXLTA4HALDH1A1CA1ACHE | |
| SCHEMBL13776504 | 0.92 | LTA4H (0.39) | PAOXLTA4HALDH1A1CA1ACHE | |
| SCHEMBL12153331 | 0.87 | CA1 (0.48) | LTA4HALDH1A1CA1TDP1CYP1A2 | |
| SCHEMBL12153332 | 0.85 | CA1 (0.46) | LTA4HCA1FFAR4FFAR1BLM | |
| SCHEMBL999059 | 0.84 | FFAR4 (0.53) | LTA4HALDH1A1FFAR4FFAR1TDP1 | |
| SCHEMBL17953993 | 0.82 | ALDH1A1 (0.47) | PAOXALDH1A1CA1ACHETDP1 | |
| SCHEMBL10188903 | 0.82 | ALDH1A1 (0.47) | PAOXALDH1A1CA1ACHETDP1 | |
| SCHEMBL13293157 | 0.82 | ALDH1A1 (0.47) | PAOXALDH1A1CA1ACHETDP1 | |
| SCHEMBL14093813 | 0.82 | FFAR4 (0.57) | ALDH1A1FFAR4FFAR1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160206680-A1 | ANTI-TRYPANOSOME COMPOUNDS AND TREATMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-21 | — | — | US | disclosed |
| US-20140221276-A1 | FURTHER NOVEL ANTI-PARASITIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206680-A1 | ANTI-TRYPANOSOME COMPOUNDS AND TREATMENTS | PDF, TUFM, TRAP1 | PAOX 307/4885LTA4H 179/4885ALDH1A1 4842/4885 |
| US-20140221276-A1 | FURTHER NOVEL ANTI-PARASITIC COMPOUNDS | PTMS, LRBA, PDF | PAOX 260/4885LTA4H 25/4885ALDH1A1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.